Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma.

This article reviews the mechanisms of carcinogenic HBV by conducting a review of the literature on the efficacy of therapy for reducing the risk of HCC. A few recent articles have suggested that tenofovir offers advantages over entecavir in terms of HCC prevention, but these articles have the inherent limitations of observational data. No other head-to-head randomized trials exist. Further randomized studies would help provide stronger evidence of the association between the type of antiviral agent and the HCC outcomes. Only achieving complete viral eradication from the liver will truly decrease the mortality and incidence of HCC. PMID: 31765553 [PubMed - in process]
Source: Korean J Gastroenter... - Category: Gastroenterology Authors: Tags: Korean J Gastroenterol Source Type: research

Related Links:

Conclusion: AP is still a rare complication after TACE. Etiology is still attributed to the occurrence of shunting and embolization drug reflux. Strategies strengthening the catheter tip that is placed as close to the distal branches of the hepatic artery for the possible careful injection of embolic materials is still the key to avoid post-TACE AP.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
THE GORDON WILSON LECTURE: THE HEPATITIS C VIRUS: FROM HIPPOCRATES TO CURE. Trans Am Clin Climatol Assoc. 2019;130:104-118 Authors: Alter HJ Abstract The modern age of viral hepatitis began in the early 1960s with the serendipitous discovery of the Australia antigen, a protein that was later shown to represent the envelope of the hepatitis B virus leading to its designation as the hepatitis B surface antigen. This was the first marker for any hepatitis virus and became not only a diagnostic assay, but also a mandatory blood donor screening test and the basis for the first generation hepatitis B vaccine...
Source: Transactions of the American Clinical and Climatological Association - Category: General Medicine Tags: Trans Am Clin Climatol Assoc Source Type: research
More than 240 million people worldwide are chronically infected with the hepatitis B virus (HBV) [1 –2]. In the Asia-Pacific region, where it is most prevalent, chronic HBV infection is the leading cause of cirrhosis, liver failure, and hepatocellular carcinoma [2–6]. While currently approved oral nucleos(t)ide analogs effectively suppress viral replication, providing important clinical benefi ts, there are several disadvantages of this therapeutic approach. First, since antiviral therapy is rarely curative, most patients must receive life-long treatment with the attendant cost, cumulative toxicity, and risk of...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
CONCLUSIONS: The included trials lacked data on all-cause mortality, health-related quality of life, serious adverse events, hepatitis-B related mortality, and hepatitis-B related morbidity. The evidence on the effect of Radix Sophorae flavescentis on the proportion of participants with adverse events considered 'not to be serious' and on the proportion of participants with detectable HBV-DNA is still unclear. We advise caution regarding the results of Radix Sophorae flavescentis showing a reduction in the proportion of people with detectable HBeAg because the trials were at high risk of bias, because it is a non-validated...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
An estimated 248 million individuals live with chronic hepatitis B infection worldwide [1]. Chronic hepatitis B infection (CH-B) has a high risk of progression to cirrhosis and hepatocellular carcinoma. Entecavir, a guanosine nucleoside analogue, is often the drug of choice in nucleoside-na ïve patients with CH-B because of its low rate of viral resistance. Resistance to entecavir therapy in nucleoside-naïve patients is approximately 1 percent after five years of treatment [2]. The efficacy and safety of entecavir has been well-studied in different patient populations with CH-B.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research
An estimated 248 million individuals live with chronic hepatitis B infection worldwide.1 Chronic hepatitis B (CH-B) infection has a high risk of progression to cirrhosis and hepatocellular carcinoma. Entecavir, a guanosine nucleoside analogue, is often the drug of choice in nucleoside-naive patients with CH-B because of its low rate of viral resistance. Resistance to entecavir therapy in nucleoside-naive patients is approximately 1% after 5 years of treatment.2 The efficacy and safety of entecavir have been well studied in different patient populations with CH-B.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letter Source Type: research
Authors: Öksüz Z, Serin MS, Serin A, Sezgin O, Gonca S Abstract HBV is a DNA virus and the causative agent of hepatitis B infection. Hepatitis B is a contagious disease and is still a major health problem all over the world. When the infection become chronic, it may cause serious diseases such as fibrosis, cirrhosis and/or hepatocellular carcinoma. Interferon/pegylated interferon by intravenous route and nucleoside/nucleotide (NA) analogues such as lamivudine, adefovir, entecavir, telbivudine and tenofovir given by oral route are used in the treatment. Antivirals given by oral route are mostly preferred i...
Source: Mikrobiyoloji Bulteni - Category: Microbiology Tags: Mikrobiyol Bul Source Type: research
Conclusion: In conclusion, Baishouwu extract exhibited potent effect on the development of HCC by altering TLR4/MyD88/ NF-κB signaling pathway in the sequence of hepatic inflammation-fibrosis-cancer, which provided novel insights into the mechanism of Baishouwu extract as a candidate for the pretreatment of HCC in the future. Introduction Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third cause of cancer-related deaths (Jemal et al., 2011). Chronic inflammation, caused by chemical, biological and physical factors, is found to be related to certain human cancers. The effe...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
This study was approved by the NCCH institutional review board and performed in compliance with our institutional guidelines. Patients positive for anti-HCV antibody or HBV antigen (HBsAg) were considered to have HCC due to chronic viral hepatitis, whereas those without anti-HCV antibody nor HBsAg were considered to have HCC by another etiology (non-B/non-C). All medical records were reviewed to summarize the patients' clinical characteristics, treatments, and outcomes based on the status of chronic viral hepatitis. The baseline clinical characteristics included age, gender, ECOG-performance status (PS), treatmen...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Chronic hepatitis B (CHB) is the common chronic viral infection worldwide, affecting approximately 350million people. [1] Because persistently high hepatitis B virus (HBV) replication is associated with an increased risk of compensated cirrhosis and hepatocellular carcinoma (HCC), [2,3] replication-suppressing antiviral therapy is administered to CHB patients to prevent liver disease progression.[4] As a matter of fact, oral antiviral agents, particularly entecavir (ETV), reduce the risk of long-term complications such as liver compensated cirrhosis and HCC, ultimately improving survivals compared to controls.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
More News: Antiviral Therapy | Cancer & Oncology | Carcinoma | Cirrhosis | Gastroenterology | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Transplant | Oral Cancer | Study | Transplants | Urology & Nephrology | Viread